357 related articles for article (PubMed ID: 32865701)
21. Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report.
Omrani AS; Zaqout A; Baiou A; Daghfal J; Elkum N; Alattar RA; Bakdach D; Abusriwil H; Mostafa AM; Alhariri B; Ambra N; Khatib M; Eldeeb AM; Merenkov Z; Fawzi Z; Hmissi SM; Hssain AA; Coyle PV; Alsoub H; Almaslamani MA; Alkhal A
J Med Virol; 2021 Mar; 93(3):1678-1686. PubMed ID: 32965715
[TBL] [Abstract][Full Text] [Related]
22. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.
Thomopoulos TP; Rosati M; Terpos E; Stellas D; Hu X; Karaliota S; Bouchla A; Katagas I; Antoniadou A; Mentis A; Papageorgiou SG; Politou M; Bear J; Donohue D; Kotanidou A; Kalomenidis I; Korompoki E; Burns R; Pagoni M; Grouzi E; Labropoulou S; Stamoulis K; Bamias A; Tsiodras S; Dimopoulos MA; Pavlakis GN; Pappa V; Felber BK
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578426
[TBL] [Abstract][Full Text] [Related]
23. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.
Rojas M; Rodríguez Y; Hernández JC; Díaz-Coronado JC; Vergara JAD; Vélez VP; Mancilla JP; Araujo I; Yepes JT; Ricaurte OB; Pardo-Oviedo JM; Monsalve DM; Acosta-Ampudia Y; Ramírez-Santana C; García PG; Landinez LA; Correales LD; Grass JS; Pérez CR; López GS; Mateus N; Mancera L; Devia RR; Orjuela JE; Parra-Moreno CR; Buitrago AA; Ordoñez IE; Osorio CF; Ballesteros N; Patiño LH; Castañeda S; Muñoz M; Ramírez JD; Bastard P; Gervais A; Bizien L; Casanova JL; Camacho B; Gallo JE; Gómez O; Rojas-Villarraga A; Pérez CE; Manrique R; Mantilla RD; Anaya JM
BMC Infect Dis; 2022 Jun; 22(1):575. PubMed ID: 35761219
[TBL] [Abstract][Full Text] [Related]
25. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
26. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma.
Karataş A; İnkaya AÇ; Demiroğlu H; Aksu S; Haziyev T; Çınar OE; Alp A; Uzun Ö; Sayınalp N; Göker H
Transfus Apher Sci; 2020 Oct; 59(5):102871. PubMed ID: 32694044
[TBL] [Abstract][Full Text] [Related]
27. Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
Kremer AE; Kremer AN; Willam C; Völkl S; Verhagen J; Achenbach S; van der Meijden ED; Lang V; Aigner M; Maier C; Tenbusch M; Korn K; Lutzny-Geier G; Spoerl S; Strauß R; Vetter M; Überla K; Neurath MF; Mackensen A; Schiffer M; Hackstein H
Eur J Immunol; 2021 Oct; 51(10):2478-2484. PubMed ID: 34350584
[TBL] [Abstract][Full Text] [Related]
28. Decrease in serum antibodies to SARS-CoV-2 in convalescent plasma donors over time.
Prus K; Alquist CR; Cancelas JA; Oh D
Transfusion; 2021 Feb; 61(2):651-654. PubMed ID: 33616966
[No Abstract] [Full Text] [Related]
29. A matched cohort study of convalescent plasma therapy for COVID-19.
Sostin OV; Rajapakse P; Cruser B; Wakefield D; Cruser D; Petrini J
J Clin Apher; 2021 Aug; 36(4):523-532. PubMed ID: 33616257
[TBL] [Abstract][Full Text] [Related]
30. Convalescent Plasma Therapy in the management of COVID-19 patients-The newer dimensions.
Mahapatra S; Rattan R; Mohanty CBK
Transfus Clin Biol; 2021 Aug; 28(3):246-253. PubMed ID: 33965621
[TBL] [Abstract][Full Text] [Related]
31. Detection of SARS-CoV-2-independent immunoregulatory activity of COVID-19 convalescent plasma.
Brox R; Achenbach S; Hackstein H
Transfusion; 2021 Nov; 61(11):3087-3093. PubMed ID: 34546583
[TBL] [Abstract][Full Text] [Related]
32. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019.
Zeng QL; Yu ZJ; Gou JJ; Li GM; Ma SH; Zhang GF; Xu JH; Lin WB; Cui GL; Zhang MM; Li C; Wang ZS; Zhang ZH; Liu ZS
J Infect Dis; 2020 Jun; 222(1):38-43. PubMed ID: 32348485
[TBL] [Abstract][Full Text] [Related]
33. Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes.
Mendoza RP; Fyke W; Daniel D; Gabutan E; Das B; Bajaj H; Easy M; Vasileva A; Colbourn R; Alawad M; Dehghani A; Lin B; Emechebe D; Patel P; Jabbar A; Nikolov DB; Giovaniello D; Kang S; Tatem L; Bromberg K; Augenbraun M; Premsrirut P; Libien J; Norin AJ
Hum Immunol; 2021 Apr; 82(4):255-263. PubMed ID: 33640208
[TBL] [Abstract][Full Text] [Related]
34. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19.
Ray Y; Paul SR; Bandopadhyay P; D'Rozario R; Sarif J; Raychaudhuri D; Bhowmik D; Lahiri A; Vasudevan JS; Maurya R; Kanakan A; Sharma S; Kumar M; Singh P; Roy R; Chaudhury K; Maiti R; Bagchi S; Maiti A; Perwez MM; Mondal A; Tewari A; Mandal S; Roy A; Saha M; Biswas D; Maiti C; Bhaduri R; Chakraborty S; Sarkar BS; Haldar A; Saha B; Sengupta S; Pandey R; Chatterjee S; Bhattacharya P; Paul S; Ganguly D
Nat Commun; 2022 Jan; 13(1):383. PubMed ID: 35046397
[TBL] [Abstract][Full Text] [Related]
35. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products.
Kenig A; Ishay Y; Kharouf F; Rubin L
Clin Immunol; 2021 Jun; 227():108723. PubMed ID: 33838340
[TBL] [Abstract][Full Text] [Related]
36. Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19.
Al-Tawfiq JA; Arabi Y
Hum Vaccin Immunother; 2020 Dec; 16(12):2973-2979. PubMed ID: 32881641
[TBL] [Abstract][Full Text] [Related]
37. The use of convalescent plasma for pediatric patients with SARS-CoV-2: A systematic literature review.
Zaffanello M; Piacentini G; Nosetti L; Franchini M
Transfus Apher Sci; 2021 Apr; 60(2):103043. PubMed ID: 33388249
[TBL] [Abstract][Full Text] [Related]
38. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ
Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627
[TBL] [Abstract][Full Text] [Related]
39. Emergence of ancient convalescent plasma (CP) therapy: To manage COVID-19 pandemic.
Dassarma B; Tripathy S; Matsabisa M
Transfus Clin Biol; 2021 Feb; 28(1):123-127. PubMed ID: 33285298
[TBL] [Abstract][Full Text] [Related]
40. Treatment of immunocompromised COVID-19 patients with convalescent plasma.
Fung M; Nambiar A; Pandey S; Aldrich JM; Teraoka J; Freise C; Roberts J; Chandran S; Hays SR; Bainbridge E; DeVoe C; Roque Gardner A; Yokoe D; Henrich TJ; Babik JM; Chin-Hong P
Transpl Infect Dis; 2021 Apr; 23(2):e13477. PubMed ID: 32989856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
